Stereotaxis announced the first patients in the United States have been treated successfully utilizing Abbott’s EnSite X EP System integrated with Stereotaxis’ Robotic Magnetic Navigation System. The integration of Abbott’s leading cardiac mapping system and Stereotaxis’ advanced robotic technology, first announced at Heart Rhythm 2023, combines highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery. The first integrated procedures in the US were completed by physicians at Weill Cornell Medical Center, Mount Sinai Morningside, Banner University Medical Center Phoenix, and Overland Park Regional Medical Center.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABT:
- Abbott director sells $4.70M in common stock
- Abbott (NYSE:ABT) Up Fractionally despite FDA Warning Letter
- Abbott announces late-breaking data from LIFE-BTK clinical trial
- Abbott reports data from trials of its heart devices to treat valve diseases
- Abbott price target lowered to $110 from $123 at Raymond James